Acute Myelogenous Leukemia: Preliminary Entry 250: Genetics, Biology and Therapy - Cancer Treatment and Research v. 145 (Hardback)
  • Acute Myelogenous Leukemia: Preliminary Entry 250: Genetics, Biology and Therapy - Cancer Treatment and Research v. 145 (Hardback)

Acute Myelogenous Leukemia: Preliminary Entry 250: Genetics, Biology and Therapy - Cancer Treatment and Research v. 145 (Hardback)

£193.00
Hardback Published: 01/05/2007
  • We can order this

Usually despatched within 3 weeks

  • This item has been added to your basket

Check Marketplace availability

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

Publisher: Springer-Verlag New York Inc.
ISBN: 9780387692579

You may also be interested in...

Your review has been submitted successfully.

We would love to hear what you think of Waterstones. Why not review Waterstones on Trustpilot?


Review us on Trustpilot